The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice
Open accessAbstract
Durability of response Optional Yes (at least 4 week) Yes (at least 4 week) Definition of measurability Yes No Yes Number of target lesions Up to 5 None specified Up to 5 T2/FLAIR Not evaluated Not evaluated Evaluated Corticosteroids considered No Yes Yes Clinical status considered No Yes Yes Pseudo-progression considered No No Yes RANO: Response Assessment in Neuro-Oncology; RECIST: Response Evaluation Criteria in Solid Tumors.oncology including brain metastases (BM), meningioma, pediatric tumors, spinal metastases and leptomeningeal disease.This review will discuss the recommendations of the various RANO working groups.Although the primary focus of the RANO effort is to improve the conduct of clinical trials, some of the recommendations may be useful in the routine care of brain tumor patients.2019) 8(1future science group CNS Oncol
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Ostrom, Q. T., Gittleman, H., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox158 · Cited by 1,800
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Response assessment criteria for brain metastases: proposal from the RANO group
Lin, N. U., Lee, E. Q., Aoyama, H., Barani, I. J., Barboriak, D. P., Baumert, B. G., Bendszus, M., Brown, P. D., Camidge, D. R., Chang, S. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70057-4 · Cited by 1,088
Self-citationImmunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationAlbert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Self-citationResponse Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 435
Self-citationLeptomeningeal metastases: a RANO proposal for response criteria
Chamberlain, M., Junck, L., Brandsma, D., Soffietti, R., Rudà, R., Raizer, J., Boogerd, W., Taillibert, S., Groves, M. D., Rhun, E. L., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now183 · Cited by 317
Self-citationUpdates in the management of brain metastases
Arvold, N. D., Lee, E. Q., Mehta, M. P., Margolin, K., Alexander, B. M., Lin, N. U., Anders, C. K., Soffietti, R., Camidge, D. R., Vogelbaum, M. A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now127 · Cited by 275
Self-citationNayak, L., DeAngelis, L. M., Brandes, A. A., Peereboom, D. M., Galanis, E., Lin, N. U., Soffietti, R., Macdonald, D. R., Chamberlain, M., Perry, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox029 · Cited by 244
Self-citationEnd Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
van den Bent, M. J., Vogelbaum, M. A., Wen, P. Y., Macdonald, D. R., & Chang, S. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4998 · Cited by 240
Self-citationTemozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms
Chakravarti, A., Erkkinen, M. G., Nestler, U., Stupp, R., Mehta, M., Aldape, K., Gilbert, M. R., Black, P. M., & Loeffler, J. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0596 · Cited by 223
Kesari, S., & Batchelor, T. T. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(02)00032-4 · Cited by 211
Taphoorn, M. J. B., Dirven, L., Kanner, A. A., Lavy-Shahaf, G., Weinberg, U., Taillibert, S., Toms, S. A., Honnorat, J., Chen, T. C., Sroubek, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5082 · Cited by 201
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J.-P., & Wilson, C. B. (1977) · Journal of Neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Gorlia, T., Stupp, R., Brandes, A. A., Rampling, R. R., Fumoleau, P., Dittrich, C., Campone, M. M., Twelves, C. C., Raymond, E., Hegi, M. E., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.004 · Cited by 186
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
van den Bent, M. J., Smits, M., Kros, J. M., & Chang, S. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6737 · Cited by 172
Brain Tumor Imaging in Clinical Trials
Henson, J. W., Ulmer, S., & Harris, G. J. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0963 · Cited by 167
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials
Avila, E. K., Chamberlain, M. C., Schiff, D., Reijneveld, J. C., Armstrong, T. S., Rudà, R., Wen, P. Y., Weller, M., Koekkoek, J. A. F., Mittal, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now190 · Cited by 139
Self-citationLin, N., Lee, E. Q., Aoyama, H., Barani, I. J., Baumert, B. G., Brown, P. D., Camidge, D. R., Chang, S. M., Dancey, J. E., Gaspar, L. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70311-5 · Cited by 136
Self-citationResponse Assessment in Neuro-Oncology
Lee, E. Q., & Wen, P. Y. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0143-y · Cited by 119
Self-citationCamidge, D. R., Lee, E. Q., Lin, N., Margolin, K. A., Ahluwalia, M. S., Bendszus, M., Chang, S. M., Dancey, J. E., de Vries, E. G. E., Harris, G. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30693-9 · Cited by 110
Self-citationPérez‐Larraya, J. G., Lahutte, M., Petrirena, G. J., Reyes-Botero, G., González-Aguilar, A., Houillier, C., Guillevin, R., Sanson, M., Hoang‐Xuan, K., & Delattre, J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos070 · Cited by 106
Wick, W., Chinot, O. L., Bendszus, M., Mason, W. P., Henriksson, R., Saran, F. H., Nishikawa, R., Révil, C., Kerloëguen, Y., & Cloughesy, T. F. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now091 · Cited by 104
López, P. D. D., Riñones‐Mena, E., & Corrales-García, E. M. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1816-x · Cited by 95
Michaelsen, S. R., Christensen, I. J., Grunnet, K., Stockhausen, M., Broholm, H., Kosteljanetz, M., & Poulsen, H. S. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-402 · Cited by 87
Warren, K. E., Poussaint, T. Y., Vézina, G., Hargrave, D. R., Packer, R. J., Goldman, S., Wen, P. Y., Pollack, I. F., Zurakowski, D., Kun, L. E., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24562 · Cited by 85
Self-citationAssessment of Brain Tumor Response: RANO and Its Offspring
Eisele, S. C., Wen, P. Y., & Lee, E. Q. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0413-5 · Cited by 81
Self-citationClinical Discussion and Review of the Management of Brain Metastases
Brastianos, P. K., Curry, W. T., & Oh, K. S. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0133 · Cited by 72
Alexander, B. M., Brown, P. D., Ahluwalia, M. S., Aoyama, H., Baumert, B. G., Chang, S. M., Gaspar, L. E., Kalkanis, S. N., Macdonald, D. R., Mehta, M. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30692-7 · Cited by 59
Self-citationCorticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group
Arvold, N. D., Armstrong, T. S., Warren, K. E., Chang, S. M., DeAngelis, L. M., Blakeley, J. O., Chamberlain, M. C., Dunbar, E. M., Loong, H. H.-F., Macdonald, D. R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy056 · Cited by 58
Self-citationHuang, R. Y., Young, R. J., Ellingson, B. M., Veeraraghavan, H., Wang, W., Tixier, F., Um, H., Nawaz, R., Luks, T. L., Kim, J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa105 · Cited by 57
Self-citationMcCoach, C. E., Berge, E. M., Lu, X. J. D., Barón, A. E., & Camidge, D. R. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.024 · Cited by 55
Wen, P. Y., Cloughesy, T. F., Ellingson, B. M., Reardon, D. A., Fine, H. A., Abrey, L. E., Ballman, K. V., Bendszuz, M., Buckner, J. C., Chang, S. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou226 · Cited by 53
Self-citationRecht, L. D., Mechtler, L. L., Wong, E. T., O'Connor, P. C., & Rodda, B. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.9455 · Cited by 42
Impact of imaging measurements on response assessment in glioblastoma clinical trials
Reardon, D. A., Ballman, K., Buckner, J. C., Chang, S. M., & Ellingson, B. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou286 · Cited by 41
Toward Precision Medicine in Brain Metastases
Berghoff, A. S., & Brastianos, P. K. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1627469 · Cited by 12
Sequencing Brain Metastases and Opportunities for Targeted Therapies
Chukwueke, U. N., & Brastianos, P. K. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0170 · Cited by 9
Self-citationCurrent and future directions for Phase II trials in high-grade glioma
Alexander, B. M., Lee, E. Q., Reardon, D. A., & Wen, P. Y. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.158 · Cited by 5
Self-citation
Cited by
Natsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Metadata
- Authors
- Chukwueke, U. N., & Wen, P. Y.
- Venue
- CNS Oncology
- Publisher
- Informa UK Limited
- Published
- 2019-02-26
- Volume
- 8
- Issue
- 1
- Pages
- CNS28-CNS28
- ISSN
- 2045-0907 (ISSN-L)
- 2045-0915
- OpenAlex
- W2916850088
- Cited by
- 256
- References
- 54
- FWCI
- 16.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.